Home Companies Catalysts Deep Dives
Ultomiris ravulizumab APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaRare Disease
Launch2018-12-21
US LOE2030-12-21
Peak Sales Est$6000M
Formulations[{"id":"ultomiris-iv","doses":"300mg/3mL, 1100mg/11mL","route":"IV","setting":"INFUSION_CENTER","fre
Companies
AZN (ORIGINATOR)100%
Mechanism: C5 inhibitor
Expert: Humanized monoclonal antibody that binds complement C5, preventing cleavage to C5a and C5b and inhibiting terminal complement-mediated hemolysis and inflammation.
Everyday: Blocks a protein in the immune system that mistakenly attacks the body's own red blood cells.
Targets: ["C5"]
Revenue History
PeriodRevenue ($M)
2023$3,578M
2024$4,312M
Q1 2025$1,180M
Q2 2025$1,250M
Programs (4)
IndicationStageKey StudyRegional Status
PNHAPPROVED301/302[{"stage":"APPROVED","region":"US","approval_date":"2018-12-21"},{"stage":"APPRO
gMG (AChR+)APPROVEDCHAMPION-MG[{"stage":"APPROVED","region":"US","approval_date":"2022-04-29"},{"stage":"APPRO
NMOSDAPPROVEDCHAMPION-NMOSD[{"stage":"APPROVED","region":"US","approval_date":"2024-08-22"}]
aHUSAPPROVED311/312[{"stage":"APPROVED","region":"US","approval_date":"2019-10-18"},{"stage":"APPRO
Upcoming Catalysts (2)
Ultomiris - IgAN - Ph3 - Topline (ICAN) H1 2026
Ultomiris - HSCT-TMA - Ph3 - Topline H1 2026
Notes
Long-acting C5 inhibitor. PNH, aHUS, gMG.
Data from Supabase · Updated 2026-03-24